Sumifilam is a small molecule commercialized by Cassava Sciences, with a leading Phase III program in Alzheimer’s Disease. According to Globaldata, it is involved in 10 clinical trials, of which 5 were completed, and 5 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Sumifilam’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Sumifilam is expected to reach an annual total of $247 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Sumifilam Overview

Simufilam (formerly known as sumifilam) is under development for the treatment of Alzheimer’s disease. The drug candidate is administered through oral route. The drug candidate is a small molecule. It targets scaffolding protein filamin A (FLNA).

Cassava Sciences Overview

Cassava Sciences, formerly Pain Therapeutics, is a clinical-stage biopharmaceutical company that develops drugs for the treatment of neuroinflammation and neurodegenerative diseases, with a special focus on Alzheimer’s disease. The company’s lead product candidate Simufilam is a small molecule being developed in phase 3 clinical trials for treatment of Alzheimer’s disease. The clinical trials are conducted in phase3 studies such as Rethink-ALZ and Refocus-ALZ. It is also investigating SavaDx, a blood-based diagnostic for detection of Alzheimer’s disease. Major investor include national institute of health of health (NIH), National Institute on aging (NIA). Cassava Sciences is headquartered in Austin, Texas, the US.

The operating loss of the company was US$32.9 million in FY2021, compared to an operating loss of US$6.5 million in FY2020. The net loss of the company was US$32.4 million in FY2021, compared to a net loss of US$6.3 million in FY2020.

For a complete picture of Sumifilam’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.